Costeff optic atrophy syndrome: New clinical case and novel molecular findings
Summary 3-Methylglutaconic aciduria (MGA) encompasses a heterogeneous group of disorders, often coinciding with elevated levels of urinary 3-methylglutaric acid. Type I MGA is a disorder of leucine metabolism, while the biological basis for the MGA is unclear for the other types (MGA types II–V). MG...
Saved in:
Published in | Journal of inherited metabolic disease Vol. 31; no. Suppl 2; pp. 419 - 423 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Dordrecht
Springer Netherlands
01.12.2008
Blackwell Publishing Ltd |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Summary
3-Methylglutaconic aciduria (MGA) encompasses a heterogeneous group of disorders, often coinciding with elevated levels of urinary 3-methylglutaric acid. Type I MGA is a disorder of leucine metabolism, while the biological basis for the MGA is unclear for the other types (MGA types II–V). MGA type III (Costeff optic atrophy syndrome, autosomal recessive optic atrophy-3 or optic atrophy plus syndrome, OMIM 258501) is distinguished by early bilateral optic atrophy, later-onset spasticity, extrapyramidal dysfunction, ataxia, and occasional cognitive deficits. It is caused by homozygous mutations in the optic atrophy 3 gene (
OPA3
). We present a case of a patient with MGA who has infantile-onset optic atrophy, ataxia, extrapyramidal movements and spasticity, but with normal intellect. Sequencing of the patient’s DNA revealed a homozygous nonsense mutation c.415C>T (p.Q139X) in exon 2 of transcript 2 of the
OPA3
gene, as well as a common silent polymorphism c.231T>C in the same exon. This is the first nonsense mutation found in
OPA3
. The molecular findings in
OPA3
are also reviewed, including mutations in
OPA3
that result in autosomal dominant optic atrophy and cataract (ADOAC). The recessive mode of inheritance of MGA type III as a result of the p.Q139X mutation is supported by the carrier status of the unaffected father. |
---|---|
Bibliography: | References to electronic databases Competing interests: None declared Methylglutaconic aciduria type I: OMIM 250950. Methylglutaconic aciduria type II (Barth syndrome): OMIM 302060. Methylglutaconic aciduria type III: OMIM 258501. Methylglutaconic aciduria type V (DCMA): 610198. Autosomal dominant optic atrophy and cataract (ADOAC): OMIM 165300. Communicating editor: Michael Gibson JIMD Short Report #134 (2008) Online ObjectType-Case Study-3 SourceType-Scholarly Journals-1 content type line 23 ObjectType-Review-1 ObjectType-Feature-5 ObjectType-Report-2 ObjectType-Article-4 |
ISSN: | 0141-8955 1573-2665 |
DOI: | 10.1007/s10545-008-0981-z |